Pharmabiz2h
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis
CAGE Bio begins phase 2b clinical trial for CGB-500, a breakthrough topical JAK inhibitor for moderate to severe atopic dermatitis: San Carlos, California Saturday, January 11, 20 ...
Pharmabiz4h
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea
Newron Pharma, Myung In Pharm ink license agreement to develop, manufacture & commercialize Newron’s evenamide in South Korea: Milan Saturday, January 11, 2025, 16:00 Hrs [IST] ...
Pharmabiz3h
FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025
FORE Biotherapeutics highlights pipeline achievements for its oncology programme; Provides objectives for 2025: Philadelphia Saturday, January 11, 2025, 17:00 Hrs [IST] FORE Bioth ...
Pharmabiz5h
SynCardia Systems gets CNIPA notification granting first patent covering company’s next-generation total artificial heart
SynCardia Systems gets CNIPA notification granting first patent covering company’s next-generation total artificial heart: Tucson, Arizona Saturday, January 11, 2025, 15:00 Hrs ...
Pharmabiz6h
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market
Gaelic Labs establishes subsidiary in UAE, enabling access to growing Middle East pharma market: Ireland Saturday, January 11, 2025, 13:30 Hrs [IST] Gaelic Laboratories, a Europea ...
Pharmabiz6h
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology
Boehringer Ingelheim broadens oncology portfolio with license for Synaffix’s ADC technology: Ingelheim Saturday, January 11, 2025, 14:00 Hrs [IST] Boehringer Ingelheim and Synaf ...
Pharmabiz7d
Centre notifies amendments to Foreign Trade Policy 2023 to enhance stakeholder engagement
The Union ministry of commerce & industry has issued a notification introducing amendments to the Foreign Trade Policy (FTP) 2023, aimed at fostering enhanced stakeholder engagement. The notification, ...
Pharmabiz7d
GSK receives China NMPA approval for Nucala to treat adults with chronic rhinosinusitis with nasal polyps
GSK plc announced that the China National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as an add-on therapy with ...
Pharmabiz7h
Seven research leaders awarded prestigious NIHR award
The NIHR has announced the latest outstanding researchers to become NIHR Research Professors. They will play a key role in undertaking professorial-level research that has a positive impact on the ...
Pharmabiz7d
Artificial intelligence and machine learning transforming ICU decision-making: Experts
Artificial intelligence (AI) and machine learning (ML) are poised to redefine the landscape of critical care medicine, offering innovative solutions to the challenges faced in intensive care units ...
Pharmabiz7d
SIGA Technologies receives Japanese approval for Tepoxx for the treatment of orthopoxviruses
SIGA Technologies, a commercial stage pharmaceutical company, announced that its antiviral treatment Tepoxx (tecovirimat 200 mg capsules), marketed as Tpoxx in the United States, has received ...
Pharmabiz8d
Hutchmed to divest its 45% equity interest in SHPL to GP Health Service Capital & Shanghai Pharma for approx. US$ 608 million
Hutchmed (China) Limited, an innovative, commercial-stage, biopharmaceutical company, announces that it has entered into two agreements to divest its 45% equity interest in Shanghai Hutchison ...